These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 24951539)

  • 1. Novel concepts in HDL pharmacology.
    Remaley AT; Norata GD; Catapano AL
    Cardiovasc Res; 2014 Aug; 103(3):423-8. PubMed ID: 24951539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel HDL-based therapeutic agents.
    Joy TR
    Pharmacol Ther; 2012 Jul; 135(1):18-30. PubMed ID: 22465158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on strategies to increase HDL quantity and function.
    Duffy D; Rader DJ
    Nat Rev Cardiol; 2009 Jul; 6(7):455-63. PubMed ID: 19488077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
    Shinkai H
    Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Niacin in cardiovascular disease: recent preclinical and clinical developments.
    Digby JE; Ruparelia N; Choudhury RP
    Arterioscler Thromb Vasc Biol; 2012 Mar; 32(3):582-8. PubMed ID: 22207729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targets.
    Catapano AL
    Nat Rev Cardiol; 2018 Jan; 15(2):75-76. PubMed ID: 29336436
    [No Abstract]   [Full Text] [Related]  

  • 7. Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.
    Miyares MA; Davis K
    Vasc Health Risk Manag; 2012; 8():483-93. PubMed ID: 22977305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CETP-Inhibition and HDL-Cholesterol: A Story of CV Risk or CV Benefit, or Both.
    Nicholls SJ
    Clin Pharmacol Ther; 2018 Aug; 104(2):297-300. PubMed ID: 29901215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel HDL-directed pharmacotherapeutic strategies.
    Degoma EM; Rader DJ
    Nat Rev Cardiol; 2011 May; 8(5):266-77. PubMed ID: 21243009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should raising high-density lipoprotein cholesterol be a matter of debate?
    Athyros VG; Katsiki N; Karagiannis A; Mikhailidis DP
    J Cardiovasc Med (Hagerstown); 2012 Apr; 13(4):254-9. PubMed ID: 22367577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk.
    Sharma RK; Singh VN; Reddy HK
    Vasc Health Risk Manag; 2009; 5():793-9. PubMed ID: 19812691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis.
    Riaz H; Khan SU; Rahman H; Shah NP; Kaluski E; Lincoff AM; Nissen SE
    Eur J Prev Cardiol; 2019 Mar; 26(5):533-543. PubMed ID: 30861690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting high-density lipoproteins: update on a promising therapy.
    Verdier C; Martinez LO; Ferrières J; Elbaz M; Genoux A; Perret B
    Arch Cardiovasc Dis; 2013 Nov; 106(11):601-11. PubMed ID: 24074699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing HDL-cholesterol and prevention of atherosclerosis: A critical perspective.
    Parhofer KG
    Atheroscler Suppl; 2015 May; 18():109-11. PubMed ID: 25936313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease.
    Windler E; Schöffauer M; Zyriax BC
    Diab Vasc Dis Res; 2007 Jun; 4(2):136-42. PubMed ID: 17654448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should HDL cholesterol levels be the primary target of cardiovascular disease risk assessment and therapy?
    Elis A
    Expert Rev Cardiovasc Ther; 2012 Jun; 10(6):675-7. PubMed ID: 22894621
    [No Abstract]   [Full Text] [Related]  

  • 18. High-density Lipoprotein (HDL) Dysfunction and the Future of HDL.
    Ertek S
    Curr Vasc Pharmacol; 2018; 16(5):490-498. PubMed ID: 29149817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Journey through cholesteryl ester transfer protein inhibition: from bench to bedside.
    Karalis I; Rensen PC; Jukema JW
    Circ Cardiovasc Qual Outcomes; 2013 May; 6(3):360-6. PubMed ID: 23674310
    [No Abstract]   [Full Text] [Related]  

  • 20. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.
    Chapman MJ; Le Goff W; Guerin M; Kontush A
    Eur Heart J; 2010 Jan; 31(2):149-64. PubMed ID: 19825813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.